Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 5:17:43-52.
doi: 10.2147/COPD.S340241. eCollection 2022.

The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening

Adriana-Maria Hiller  1 , Eeva Piitulainen  1 , Hanan Tanash  1
Affiliations

The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening

Adriana-Maria Hiller et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Background: Severe alpha-1-antitrypsin deficiency (AATD) is a genetic condition predisposing to chronic obstructive pulmonary disease (COPD) and liver disease. Its natural course is not well known. Our aim was to study the natural course of AATD by analyzing the clinical course in individuals with severe AATD identified by screening.

Materials and methods: Of the 1585 individuals included in the Swedish AATD register, 377 (24%) were identified by screening and included in this retrospective study. The follow-up time was from the date of inclusion in the register to the first lung transplantation, death or the termination of the study on June 1st, 2016. The risk factors for having a diagnosis of COPD were investigated through a proportional hazards model, adjusted for sex, diagnosis before the age of 14 years, smoking habits, occupational exposure to airway irritants and respiratory symptoms or diseases.

Results: At inclusion, 71% of the individuals were asymptomatic, ie, without any respiratory symptoms. Compared to the 156 (41%) ever-smokers, the 221 (59%) never-smokers had better lung function (mean FEV1 98 (SD 18) vs 85 (SD 28) % predicted; p < 0.001), and fewer of them were symptomatic, ie, with respiratory symptoms, at inclusion (20% vs 42%; p < 0.001). They also had a lower annual decline in FEV1 (mean 42 (95% CI 36-47) vs 53 (95% CI 47-60) mL·yr-1; p = 0.011) and better survival than the ever-smokers. The risk factors for having a diagnosis of COPD were the identification of severe AATD at an age of ≥14 years and the presence of respiratory symptoms or diseases.

Conclusion: Never-smoking individuals with severe AATD identified by screening have better lung function, fewer symptoms, and better survival compared with the ever-smokers. Screening for AATD at an early age may improve the prognosis of AATD.

Keywords: alpha-1-antitrypsin; clinical course; lung function; prognosis; screening.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

Figures

Figure 1
Figure 1
The enrollment flow chart of the individuals included in the Swedish AATD register, stratified by the mode of identification. The subjects identified by screening are subdivided by smoking habits and presence of respiratory symptoms or diagnoses at inclusion (symptomatic) or not (asymptomatic).
See this image and copyright information in PMC

References

    1. Strnad P, McElvaney NG, Lomas DA. Alpha1-Antitrypsin deficiency. N Engl J Med. 2020;382:1443–1455. doi:10.1056/NEJMra1910234 - DOI - PubMed
    1. American Thoracic Society; European Respiratory Society. American Thoracic Society/ European Respiratory Society Statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900. doi:10.1164/rccm.168.7.818 - DOI - PubMed
    1. Piitulainen E, Mostafavi B, Tanash HA. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37–40 years. Int J Chron Obstruct Pulmon Dis. 2017;12:495–500. doi:10.2147/COPD.S120241 - DOI - PMC - PubMed
    1. Hiller AM, Piitulainen E, Jehpsson L, Tanash H. Decline in FEV1 and hospitalized exacerbations in individuals with severe alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2019;14:1075–1083. doi:10.2147/COPD.S195847 - DOI - PMC - PubMed
    1. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200.000 infants. N Engl J Med. 1976;294:1316–1321. doi:10.1056/NEJM197606102942404 - DOI - PubMed

MeSH terms